Filtered By:
Specialty: Cardiology
Drug: Angiomax
This page shows you your search results in order of date.
Order by Relevance | Date
Total 30 results found since Jan 2013.
Frequency and predictors of diagnostic coronary angiography and percutaneous coronary intervention related to stroke
CONCLUSIONS: Based on the large national registry, PCI ± DCA is associated with fewer risk factors and lower rate of periprocedural strokes than isolated DCA.PMID:34472076 | DOI:10.33963/KP.a2021.0100
Source: Kardiologia Polska - September 2, 2021 Category: Cardiology Authors: Bart łomiej Staszczak Krzysztof P Malinowski Wojciech Wa ńha Zbigniew Siudak Magdalena J ędrychowska Micha ł Susuł S ławomir Surowiec Szymon Darocha Andrzej Surdacki Marcin Kurzyna Wojciech Wojakowski Jacek Legutko Krzysztof Bartu ś Stanis ław Bar Source Type: research
Periprocedural Bivalirudin Versus Unfractionated Heparin During Percutaneous Coronary Intervention Following Fibrinolysis for ST-Segment Elevation Myocardial Infarction.
CONCLUSION: The periprocedural use of bivalirudin vs UFH was associated with similar rates of MACE and bleeding. Given the expense of bivalirudin and lack of demonstrable clinical superiority, UFH remains the first-line periprocedural anticoagulant in a pharmacoinvasive strategy.
PMID: 31786531 [PubMed - in process]
Source: The Journal of Invasive Cardiology - December 2, 2019 Category: Cardiology Tags: J Invasive Cardiol Source Type: research
Patients treated with bivalirudin are still at higher risk of stent thrombosis: a comprehensive meta-analysis of randomised clinical trials of bivalirudin and heparin for percutaneous coronary interventions.
CONCLUSIONS: The advantages of bivalirudin are undoubtedly related to GPI use in the heparin arms. Bivalirudin-based regimens are more beneficial when compared with heparin and planned GPI use in terms of NACE and major bleedings; this was not observed when compared to heparin and provisional GPI use. Regardless of adjunctive GPI use, stent thrombosis episodes were significantly more common in bivalirudin-treated subjects. Therefore, the safety and economic issues may urge revision of this aspect of current clinical practice and guidelines.
PMID: 29350380 [PubMed - indexed for MEDLINE]
Source: Kardiologia Polska - December 12, 2018 Category: Cardiology Authors: Grajek S, Michalak M, Gwizdała A, Araszkiewicz A, Grygier M, Hiczkiewicz J, Lesiak M Tags: Kardiol Pol Source Type: research
Efficacy and safety of bivalirudin for percutaneous coronary intervention in acute coronary syndromes: a meta-analysis of randomized-controlled trials
ConclusionsCompared with heparin, bivalirudin was associated with a similar incidence of ischemic events following PCI for ACS. An association of bivalirudin with decreased bleeding was not seen with balanced use of GPI.
Source: Clinical Research in Cardiology - April 13, 2018 Category: Cardiology Source Type: research
Patients treated with bivalirudin still at higher risk of stent thrombosis: a comprehensive meta-analysis of randomized clinical trials of bivalirudin and heparin for percutaneous coronary interventions.
CONCLUSIONS: Advantages of bivalirudin are undoubtedly related to GPI use in the heparin arms. Bivalirudin-based regimens are more beneficial when compared with heparin and planned GPI use in terms of NACE and major bleedings. It was not observed when compared to heparin and provisional GPI use. Regardless of adjunctive GPI use, stent thrombosis episodes were significantly more common in bivalirudin treated subjects. Therefore the safety and economic issues may urge revision of this aspect of current clinical practice and guidelines.
PMID: 29350380 [PubMed - as supplied by publisher]
Source: Polish Heart Journal - January 19, 2018 Category: Cardiology Authors: Grajek S, Michlak M, Gwizdała A, Araszkiewicz A, Grygier M, Hiczkiewicz J, Lesiak M Tags: Kardiol Pol Source Type: research
Comparison of Heparin and Bivalirudin in Patients Undergoing Orbital Atherectomy.
CONCLUSION: Both heparin and bivalirudin were safe and effective antithrombotic agents for patients who underwent orbital atherectomy. A randomized trial is needed to determine the antithrombotic agent of choice for orbital atherectomy.
PMID: 29086730 [PubMed - in process]
Source: The Journal of Invasive Cardiology - November 2, 2017 Category: Cardiology Tags: J Invasive Cardiol Source Type: research
Bivalirudin versus heparin in patients undergoing percutaneous transcatheter aortic valve interventions: A systematic review and meta ‐analysis
ConclusionsIn patient undergoing aortic valve interventions, no difference was seen between the use of bivalirudin and heparin as the procedural anticoagulant agent, except for a significant lower myocardial infarction events when bivalirudin was used. Further large randomized trials are needed to confirm current results.
Source: Journal of Interventional Cardiology - August 21, 2017 Category: Cardiology Authors: Pedro A. Villablanca, Rasha Al ‐Bawardy, Divyanshu Mohananey, Carola Maraboto, Michael Weinreich, Tanush Gupta, David F. Briceno, Harish Ramakrishna Tags: ORIGINAL INVESTIGATION Source Type: research
Outcomes in elderly and young patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with bivalirudin versus heparin: pooled analysis from the EUROMAX and HORIZONS-AMI trials
Conclusions In a large group of elderly patients enrolled in the EUROMAX and HORIZONS-AMI trials, bivalirudin was associated with lower 30-day rates of non-CABG major bleeding, subacute ST and NACE, with similar 30-day rates of acute ST and mortality.
Source: American Heart Journal - August 18, 2017 Category: Cardiology Source Type: research
Outcomes in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction Via Radial Access Anticoagulated With Bivalirudin Versus Heparin: A Report From the National Cardiovascular Data Registry
Conclusions
In patients undergoing primary PCI via transradial access anticoagulated with bivalirudin or heparin, there was no difference in the composite endpoint of death, myocardial infarction, or stroke.
Source: Journal of the American College of Cardiology: Cardiovascular Interventions - June 5, 2017 Category: Cardiology Authors: Jovin, I. S., Shah, R. M., Patel, D. B., Rao, S. V., Baklanov, D. V., Moussa, I., Kennedy, K. F., Secemsky, E. A., Yeh, R. W., Kontos, M. C., Vetrovec, G. W. Tags: Coronary Source Type: research
Effect of postprocedural full ‐dose infusion of bivalirudin on acute stent thrombosis in patients with ST‐elevation myocardial infarction undergoing primary percutaneous coronary intervention: Outcomes in a large real‐world population
ConclusionPost‐PCI full‐dose bivalirudin infusion is safe and has a trend to protect against acute ST in STEMI patients undergoing primary PCI in real‐world settings.
Source: Cardiovascular Therapeutics - May 12, 2017 Category: Cardiology Authors: Heyang Wang, Zhenyang Liang, Yi Li, Bin Li, Junming Liu, Xueyi Hong, Xin Lu, Jiansheng Wu, Wei Zhao, Qiang Liu, Jian An, Linfeng Li, Fanli Pu, Qiang Ming, Yaling Han Tags: ORIGINAL RESEARCH ARTICLE Source Type: research
Effect of Post ‐procedural Full Does Infusion of Bivalirudin on Acute Stent Thrombosis in Patients with ST‐elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Outcomes in a large real‐world population
ConclusionPost‐PCI full‐does bivalirudin infusion is safe and has a trend to protect against acute ST in STEMI patients undergoing primary PCI in real world settings.This article is protected by copyright. All rights reserved.
Source: Cardiovascular Therapeutics - January 13, 2017 Category: Cardiology Authors: Heyang Wang, Zhenyang Liang, Yi Li, Bin Li, Junming Liu, Xueyi Hong, Xin Lu, Jiansheng Wu, Wei Zhao, Qiang Liu, Jian An, Linfeng Li, Fanli Pu, Qiang Ming, Yaling Han Tags: Original Research Article Source Type: research
Efficacy and safety of prehospital administration of unfractionated heparin, enoxaparin or bivalirudin in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: Insights from the ORBI registry.
CONCLUSION: In this prospective registry, there were no significant differences in the rates of in-hospital MACE or major bleeding after prehospital initiation of UFH, enoxaparin or bivalirudin in patients treated by primary PCI for STEMI.
PMID: 27818120 [PubMed - as supplied by publisher]
Source: Archives of Cardiovascular Diseases - November 2, 2016 Category: Cardiology Authors: Auffret V, Leurent G, Boulmier D, Bedossa M, Zabalawi A, Hacot JP, Coudert I, Filippi E, Castellant P, Rialan A, Rouault G, Druelles P, Boulanger B, Treuil J, Avez B, Le Guellec M, Gilard M, Le Breton H Tags: Arch Cardiovasc Dis Source Type: research
Effectiveness and Safety of Bivalirudin During Percutaneous Coronary Intervention in Acute Coronary Syndrome in the Real World: CARTAGOMAX Study
Abstract: The CARTAGOMAX study assessed the safety and efficacy of bivalirudin during real-world cardiac intervention. This was a single-center prospective study. Patients with acute coronary syndrome undergoing percutaneous coronary intervention were anticoagulated with bivalirudin alone or unfractionated heparin plus a glycoprotein IIb/IIIa inhibitor. Propensity score matching was performed to control for baseline imbalances and yielded 1168 patients. There was lower incidence of the composite outcome of death from any cause or major bleeding at 30 days (P = 0.005), 6 months (P = 0.005), and 12 months (P = 0.001) of foll...
Source: Journal of Cardiovascular Pharmacology - September 1, 2016 Category: Cardiology Tags: Original Article Source Type: research
Cerebral Embolism During Transcatheter Aortic Valve Replacement The BRAVO-3 MRI Study
ConclusionsThis study documented cerebral embolization in nearly two-thirds of patients during contemporary TAVR. There were no significant differences in cerebral embolization for bivalirudin versus heparin anticoagulation during TAVR. (Open-Label, Randomized Trial in Patients Undergoing TAVR to Determine Safety and Efficacy of Bivalrudin vs. UFH [BRAVO-2/3]; NCT01651780)
Source: Journal of the American College of Cardiology - August 2, 2016 Category: Cardiology Source Type: research
